Dr. Steven Shak on the Results of the TAILORx Trial for Breast Cancer
Shak says the study examined the prospective outcomes of 1626 women and showed that at 5 years, less than 1% of women had a distant recurrence.
Steven Shak, MD, chief Scientific Officer, Oncotype Dx, discusses the good news for patients with breast cancer emerging from the NCI-sponsored Trial Assigning Individualized Options for Treatment (Rx), or TAILORx, trial.
The goal of the trial was to examine the effects of chemotherapy in patients with breast cancer who had a midrange recurrent score from 12 to 25. The analysis includes additional single gene results from patients with recurrence scores less than 11 who received hormonal therapy alone.
NGS and ctDNA Considered in Advanced Breast Cancer After Progression
May 3rd 2024During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
